We present an intricate convergence model indicating a dual-phase regulation downstream to progesterone treatment to regulate the expression of serum- and glucocorticoid-regulated kinase gene 1 (SGK1), predominantly driven as a direct transcriptional target, consistent with earlier reports (20, 21), in PR-positive breast cancer cells and down-regulation of miR-29a and miR-101-1 targeting SGK1 with a relatively distinct effect in PR-negative breast cells in response to progesterone. The gene discussed is PGR; the disease is breast cancer.